RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy

The molecular rationale to induce synthetic lethality, by targeting defective homologous recombination repair in triple negative breast cancer (TNBC), has proven to have several shortcomings. Not meeting the expected minimal outcomes in clinical trials has highlighted common clinical resistance mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiegmans, Adrian P., Miranda, Mariska, Wen, Shu Wen, Al-Ejeh, Fares, Möller, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312370/
https://www.ncbi.nlm.nih.gov/pubmed/27507046
http://dx.doi.org/10.18632/oncotarget.11065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312370/
https://www.ncbi.nlm.nih.gov/pubmed/27507046
http://dx.doi.org/10.18632/oncotarget.11065

Ejemplares similares